Ads
related to: enfortumab vedotin success rate 40- About PADCEV®
Discover How PADCEV® Treatment
May Work For You.
- Tips For Caregivers
Learn How to Better Support Your
Loved One During Treatment .
- PADCEV® Support Solutions
Access & Reimbursement Assistance
and Patient Coverage Support.
- PADCEV® Efficacy Info
Learn About How PADCEV® Was
Studied and View Trial Results.
- About PADCEV®
Search results
Results from the WOW.Com Content Network
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.
In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. [1] It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and ...
Enfortumab vedotin: Iptacopan: To treat paroxysmal nocturnal hemoglobinuria [4] Ivosidenib: Lecanemab: To treat Alzheimer's disease [4] Miglustat: Nedosiran: To lower urinary oxalate levels in primary hyperoxaluria type 1 and relatively preserved kidney function [4] Nirogacestat: To treat desmoid tumors [4] Pembrolizumab: Sutimlimab: Talquetamab
Tisotumab vedotin, sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. [1] It is a combination of tisotumab, a monoclonal antibody against tissue factor , and monomethyl auristatin E (MMAE), a potent inhibitor of cell division .
Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer.The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States.
[7] [14] The overall response rate in these adults was 32.2%, with 2.3% having a complete response and almost 30% having a partial response. [7] The response lasted for a median of approximately five-and-a-half months. [7] The trial was conducted in Asia, Europe, and the United States. [14] Erdafitinib received an accelerated approval. [7]
Ads
related to: enfortumab vedotin success rate 40